Equitable Access to Molecular Testing and Treatment Prioritization

EP: 1.The Evolution of ALK+ NSCLC Care

EP: 2.Lorlatinib in Focus: Survival, Brain Metastases, and Beyond

EP: 3.Choosing Wisely: Insights from an MAIC and eXalt3

EP: 4.Applying Trial Data to Real-World Practice in ALK+ NSCLC

EP: 5.Key Differences Among ALK Inhibitors

EP: 6.Navigating ALK Inhibitor Toxicities

EP: 7.Lorlatinib’s Unique Challenges: Managing Cognitive and Metabolic AEs

EP: 8.Long-Term Success: Educating and Supporting Patients on ALK Inhibitors

Now Viewing

EP: 9.Equitable Access to Molecular Testing and Treatment Prioritization

EP: 10.Next Steps: Post-Frontline Therapies and Resistance in ALK+ NSCLC

Molecular Testing and Biomarker Considerations

Key Themes:

• Barriers to equitable access for comprehensive molecular testing
• Strategies to overcome testing barriers
• Treatment prioritization when ALK+ status coexists with other actionable biomarkers

Notable Insights:

• Dr Dietrich identified barriers to comprehensive molecular testing including NGS
• Grizzard offered suggestions for clinicians to overcome testing barriers

Dr Lovly addressed treatment prioritization in patients with both ALK+ status and other biomarkers (eg, PD-L1 >1%)